Mithra Reports 2017 Annual Results

  • Significant operational progress for highly promising E4 (Estetrol)-based pipeline, including 5th generation oral contraceptive Estelle® and next-generation menopause therapy Donesta®
  • Important commercialization partnerships established with leaders in Women’s Health, including Libbs for Estelle® in Brazil, Fuji Pharma for Donesta® in Japan & ASEAN and Mayne Pharma for Myring™ in the US
  • Strong revenue increase and improved EBIT thanks to accelerating business development activity and solid Benelux operations

Liège, Belgium, 2 March 2018 – 7:30 AM : Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on Women’s Health, today announces its results for the year ended 31 December 2017, prepared in accordance with IFRS.